Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3650543 | 1.00 | HDAC6 (0.45) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL3647482 | 1.00 | HDAC6 (0.45) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL3651811 | 0.84 | RET (0.42) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL16301144 | 0.80 | EPHX2 (0.49) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL24841684 | 0.76 | EPHX2 (0.51) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL24841689 | 0.76 | EPHX2 (0.51) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL8262072 | 0.75 | HDAC6 (0.48) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL12796767 | 0.75 | HDAC6 (0.48) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL14590371 | 0.75 | HDAC6 (0.48) | HDAC6MAPK14RETCAMK1DEPHX2 | |
| SCHEMBL14608700 | 0.75 | HDAC6 (0.48) | HDAC6MAPK14RETCAMK1DEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207766-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | Abbott Products GmbH (DE) | 2010-07-21 | — | — | EP | claimed |
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | US | claimed |
| WO-2009050252-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| EP-2207766-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | Abbott Products GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009050252-A1 | NOVEL SULFAMATE COMPOUNDS FOR MEDICAL USE | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104126-A1 | Sulfamate Compounds and Uses Thereof | SULT1A1, SULT1E1, SULT2A1 | HDAC6 265/4885MAPK14 3761/4885RET 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.